Medigen Biotechnology (ROCO:3176) Beginning Cash Position : NT$2,223 Mil (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Medigen Biotechnology Beginning Cash Position?

Medigen Biotechnology's Beginning Cash Position for the quarter that ended in Mar. 2024 was NT$2,223 Mil.

Medigen Biotechnology's quarterly Beginning Cash Position declined from Sep. 2023 (NT$1,473 Mil) to Dec. 2023 (NT$1,262 Mil) but then increased from Dec. 2023 (NT$1,262 Mil) to Mar. 2024 (NT$2,223 Mil).

Medigen Biotechnology's annual Beginning Cash Position declined from Dec. 2021 (NT$2,207 Mil) to Dec. 2022 (NT$2,145 Mil) and declined from Dec. 2022 (NT$2,145 Mil) to Dec. 2023 (NT$2,041 Mil).

Medigen Biotechnology Beginning Cash Position Historical Data

The historical data trend for Medigen Biotechnology's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigen Biotechnology Beginning Cash Position Chart

Medigen Biotechnology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

568.55

813.69

2,206.58

2,144.58

2,040.63

Medigen Biotechnology Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beginning Cash Position	Get a 7-Day Free Trial															2,040.63	1,714.09	1,473.49	1,262.41	2,222.93

Medigen Biotechnology Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Medigen Biotechnology Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Medigen Biotechnology's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Medigen Biotechnology (ROCO:3176) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigen Biotechnology Corp (ROCO:3176) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560

Website

https://www.medigen.com.tw

Medigen Biotechnology Corp is a biopharmaceutical company primarily engaged in new drug development, drug discovery, molecular diagnostics, vaccine, and generic drugs. The new drug development business focuses mainly on the clinical stage of drug development and includes PI-88 MUPAFOSTAT for the treatment of liver cancer and OBP-301 treatment using adenovirus targeted to cancer cells only. Drug discovery includes the development of human-native mAbs for therapeutic applications related to infectious diseases. Generic drugs include pharmaceuticals for infectious diseases (antibiotics), contraceptives, nutrition milk powder, vitamin C tablets, dermatologic agents, and eye care products.

Medigen Biotechnology (ROCO:3176) Headlines

No Headlines